swisspartners Ltd. bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,178 shares of the medical research company’s stock, valued at approximately $277,000.
Other large investors have also recently added to or reduced their stakes in the company. Bailard Inc. increased its stake in Agilent Technologies by 6.2% in the fourth quarter. Bailard Inc. now owns 2,394 shares of the medical research company’s stock valued at $284,000 after acquiring an additional 140 shares during the last quarter. Savant Capital LLC bought a new stake in shares of Agilent Technologies in the 4th quarter valued at $209,000. CIBC Asset Management Inc boosted its position in Agilent Technologies by 2.7% during the fourth quarter. CIBC Asset Management Inc now owns 42,897 shares of the medical research company’s stock valued at $5,083,000 after acquiring an additional 1,145 shares during the last quarter. State of Wisconsin Investment Board grew its stake in Agilent Technologies by 4.0% during the fourth quarter. State of Wisconsin Investment Board now owns 305,776 shares of the medical research company’s stock worth $36,231,000 after purchasing an additional 11,900 shares during the period. Finally, GSA Capital Partners LLP acquired a new stake in shares of Agilent Technologies during the 4th quarter worth approximately $264,000.
Agilent Technologies stock traded down $1.06 during trading hours on Friday, hitting $142.00. 13,175 shares of the stock traded hands, compared to its average volume of 1,618,289. Agilent Technologies, Inc. has a 1 year low of $83.71 and a 1 year high of $143.35. The firm’s 50 day moving average price is $133.70. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.00 and a quick ratio of 1.62. The firm has a market capitalization of $43.09 billion, a PE ratio of 48.01, a price-to-earnings-growth ratio of 2.54 and a beta of 1.00.
Agilent Technologies announced that its Board of Directors has authorized a stock repurchase program on Tuesday, February 16th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 5% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 28th. Shareholders of record on Tuesday, July 6th will be issued a $0.194 dividend. The ex-dividend date is Friday, July 2nd. This represents a $0.78 dividend on an annualized basis and a yield of 0.55%. Agilent Technologies’s payout ratio is currently 23.78%.
In other news, SVP Michael Tang sold 500 shares of the stock in a transaction dated Friday, April 23rd. The shares were sold at an average price of $137.00, for a total transaction of $68,500.00. Following the sale, the senior vice president now owns 53,030 shares of the company’s stock, valued at $7,265,110. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Padraig Mcdonnell sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, May 28th. The shares were sold at an average price of $138.42, for a total transaction of $138,420.00. Following the completion of the transaction, the vice president now directly owns 16,916 shares of the company’s stock, valued at approximately $2,341,512.72. The disclosure for this sale can be found here. Insiders have sold 49,079 shares of company stock worth $6,544,104 over the last 90 days.
A number of analysts have commented on A shares. Redburn Partners upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating in a research note on Friday, March 19th. SVB Leerink raised their target price on Agilent Technologies from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Wednesday, May 26th. Bank of America upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and set a $147.00 price objective on the stock in a research note on Wednesday, February 17th. Canaccord Genuity upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $85.00 to $100.00 in a research report on Thursday, May 13th. Finally, Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a report on Friday, May 28th. Four research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. Agilent Technologies currently has an average rating of “Buy” and a consensus price target of $113.69.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.